Your browser doesn't support javascript.
loading
Impact of Testosterone Solution 2% on Ejaculatory Dysfunction in Hypogonadal Men.
Maggi, Mario; Heiselman, Darell; Knorr, Jack; Iyengar, Smriti; Paduch, Darius A; Donatucci, Craig F.
Afiliação
  • Maggi M; Department of Clinical Physiopathology, University of Florence, Florence, Italy.
  • Heiselman D; Eli Lilly and Company, Indianapolis, IN, USA. Electronic address: heiselman_darell_e@lilly.com.
  • Knorr J; Eli Lilly and Company, Indianapolis, IN, USA.
  • Iyengar S; Eli Lilly and Company, Indianapolis, IN, USA.
  • Paduch DA; Department of Urology, Weill Cornell Medical College, New York, NY, USA.
  • Donatucci CF; Eli Lilly and Company, Indianapolis, IN, USA.
J Sex Med ; 13(8): 1220-6, 2016 08.
Article em En | MEDLINE | ID: mdl-27436077
ABSTRACT

INTRODUCTION:

Hypogonadism is defined as decreased testosterone levels in men. Hypogonadism can be accompanied by erectile, orgasmic, and ejaculatory dysfunction.

AIMS:

To evaluate whether treatment with testosterone solution 2% (testosterone) could improve ejaculatory function in a cohort of hypogonadal men.

METHODS:

Sexually active, hypogonadal men at least 18 years old (total testosterone < 300 ng/dL) were randomized to receive testosterone or placebo for 12 weeks. MAIN OUTCOME

MEASURES:

Effects of testosterone on primary outcomes were evaluated using the International Index of Erectile Function (IIEF) and the Men's Sexual Health Questionnaire, Ejaculatory Dysfunction, Short Form (MSHQ-EjD-SF) questionnaires. Treatment differences were calculated using analysis of covariance.

RESULTS:

In total, 715 men (mean age = 55 years) were randomized to placebo (n = 357) or testosterone (n = 358). Most sexually active men who reported IIEF scores had some degree of erectile dysfunction (IIEF erectile function score < 26). Although ejaculatory function score (MSHQ-EjD-SF) improved in the testosterone group compared with placebo (P < .001), improvement on the "bother" item did not reach statistical significance. Treatment-related adverse events in the testosterone group affecting at least 1% of patients were increased hematocrit, upper respiratory tract infection, arthralgia, burning sensation, fatigue, increased prostate-specific antigen, erythema, and cough. Few patients in either treatment group developed at least one adverse event leading to discontinuation (testosterone = 1.98% vs placebo = 3.09%; P = .475).

CONCLUSION:

Hypogonadal men receiving testosterone solution 2% therapy experience significantly greater improvement in ejaculatory function, compared with placebo, as assessed by the MSHQ-EjD-SF. However, improvement in "bother" was not statistically different between the two groups. Testosterone therapy was generally well tolerated.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Testosterona / Hipogonadismo / Androgênios Tipo de estudo: Clinical_trials Limite: Adult / Aged / Humans / Male / Middle aged Idioma: En Revista: J Sex Med Assunto da revista: GINECOLOGIA / MEDICINA REPRODUTIVA / UROLOGIA Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Itália

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Testosterona / Hipogonadismo / Androgênios Tipo de estudo: Clinical_trials Limite: Adult / Aged / Humans / Male / Middle aged Idioma: En Revista: J Sex Med Assunto da revista: GINECOLOGIA / MEDICINA REPRODUTIVA / UROLOGIA Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Itália